[Topical pimecrolimus and tacrolimus and the risk of cancer].
In this review the controversy regarding the association between topical pimecrolimus and tacrolimus and the development of tumors is unfolded. After reviewing the literature we conclude that, currently, there is no scientific evidence of an increased incidence of skin cancer, lymphomas or systemic immunosuppression in those patients that use or have used topical calcineurin inhibitors. Published studies lack adequate number of patients and/or the follow-up time is short enough to conclude that topical use of calcineurin inhibitors might be associated with the reported cases of skin cancer and lymphoma. Nevertheless the possibility of long term cutaneous and/or systemic side effects cannot be excluded.
Sánchez-Pérez
J
J
Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid. jsanchezperez@aedv.es
D000287:Administration, Topical; D000818:Animals; D065095:Calcineurin Inhibitors; D006801:Humans; D012307:Risk Factors; D012878:Skin Neoplasms / Q000139:chemically induced*; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
D065095:Calcineurin Inhibitors; C117268:pimecrolimus; D016559:Tacrolimus